- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–12 of 24
Clinical Questions Addressed by the CER (1 of 2)
Presentation: Noncyclic Chronic Pelvic Pain Therapies for Women
Keywords: comparative effectiveness | systematic review | key question
Knowledge Gaps and Future Research Needs (2 of 2)
Presentation: Noncyclic Chronic Pelvic Pain Therapies for Women
Keywords: additional support | adherence | BP | clinical events | followup | future research needs | outcomes | SMBP | trials | knowledge gaps
Background: Treatment-Resistant Depression
Introduction to Atypical Antipsychotics (3 of 4)
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: aripiprazole | atypical antipsychotics | autism | autism spectrum disorders | bipolar | major depressive disorder | MDD | off-label | olanzapine | quetiapine | risperidone | second generation | antipsychotics
Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (1 of 2)
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: assessment BEHAVE-AD | atypical antipsychotics | BMI | BPRS | dementia | eating disorders | generalized anxiety disorder | HAM-A | HAM-D | MADRS | major depressive disorder | MDD | NPI | obsessive-compulsive disorder | OCD | off-label | second generation | YBOCS | antipsychotics
Summary of Studies Included in the Comparative Effectiveness Review (2 of 2)
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | dementia | major depressive disorder | obsessive-compulsive disorder | borderline personality disorder | post-traumatic stress disorder | substance abuse | eating disorders | anxiety | insomnia | MDD | OCD | BPD | PTSD
Results: Atypical Antipsychotics for Major Depressive Disorder (1 of 2)
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | major depressive disorder | MDD | risperidone | ziprasidone | SSRI | SNRI | sertraline | quetiapine XR | olanzapine | fluoxetine | HAM-D | MADRS
Summary of Benefits: Atypical Antipsychotics for Major Depressive Disorder
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | SSRI | SNRI | major depressive disorder | MDD | risperidone | ziprasidone | quetiapine | olanzapine | monotherapy
Conclusions (1 of 3)
Presentation: Off-Label Use of Atypical Antipsychotics: An Update
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | extrapyramidal symptoms | mortality | adverse effects | anorexia nervosa | substance abuse | dementia | MDD | major depressive disorder | OCD | obsessive-compulsive disorder | PTSD | post-traumatic stress disorder | generalized anxiety | borderline personality
Outline of Material
Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review (CER) Development
Background: Prevalence of Depressive Disorders
Your slide tray is being processed.